TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...
Suzhou Shengdiya Biopharmaceutical, filiale de Jiangsu Hengrui Pharmaceuticals , a obtenu l'approbation de l'Administration nationale des produits médicaux de Chine pour l'essai clinique de ...
À la Bourse de Paris, Genfit profite de l'obtention de ce statut réglementaire, et gagne encore 4,6% à 9,30 euros ce mardi 10 mars vers 15h, après avoir pris plus de 9% au plus haut de la séance.
Add Yahoo as a preferred source to see more of our stories on Google. Longtime News4Jax morning anchor Bruce Hamilton says that he is being treated for “an aggressive and progressive form of cancer.” ...
Mayo Clinic collaborated with New Phase Ltd. to install the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the U.S. Hyperthermia is a procedure that uses heat to ...
Lung cancer in never-smokers challenges lifestyle-based assumptions and underscores the need to address stigma that can delay evaluation and psychosocial support. Subtle, prolonged respiratory or ...
Dave Coulier’s tongue cancer is officially in remission, two months after going public with his diagnosis. “It’s been a roller-coaster ride for sure,” Coulier, 66, said during a Wednesday, February 4, ...
The biggest stories of the day delivered to your inbox.
A growing body of research provides a better understanding of cancer’s causes, especially possible links to alcohol, food and behaviors. About 2.1 million people in the U.S. are expected to be ...
Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results